Literature DB >> 25366383

Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Tarang Taghvaei1, Iradj Maleki, Farshad Nagshvar, Hafez Fakheri, Vahid Hosseini, Seyed Mohammad Valizadeh, Hassan Neishaboori.   

Abstract

Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory large bowel disease with recurrent variable periods of exacerbation. The aim of the current study is to evaluate the correlation of UCEIS with fecal calprotectin (FC) level to assess disease activity in UC patients in order to determine whether FC can prognosticate clinical outcome and disease activity of UC instead of colonoscopic evaluation. Our endoscopic investigations revealed the extension of UC as the following: proctitis (11.6%), procto-sigmoiditis (18.5%), left-sided colitis (15.8%), extensive colitis (11.7%), and normal endoscopy (42.4%). Conclusively, we suggest that FC can be used as a reliable tool to evaluate disease activity in ulcerative colitis patients. Moreover, our findings indicate a significant correlation between FC level and mucosal healing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366383     DOI: 10.1007/s11739-014-1144-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  33 in total

Review 1.  Review article: biological activity markers in inflammatory bowel disease.

Authors:  D Desai; W A Faubion; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2007-01-08       Impact factor: 8.171

Review 2.  Diagnostics of inflammatory bowel disease.

Authors:  Susanna Nikolaus; Stefan Schreiber
Journal:  Gastroenterology       Date:  2007-11       Impact factor: 22.682

3.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

Review 4.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

5.  Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Twyla Mueller; Andreas Rueffer; Guenther Spahn; Andreas Michalsen; Gustav J Dobos
Journal:  Inflamm Bowel Dis       Date:  2005-12       Impact factor: 5.325

6.  Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients.

Authors:  Makoto Naganuma; Hitoshi Ichikawa; Nagamu Inoue; Taku Kobayashi; Susumu Okamoto; Tadakazu Hisamatsu; Takanori Kanai; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-04-17       Impact factor: 7.527

7.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

Review 8.  The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications.

Authors:  H A Carpenter; N J Talley
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

Review 9.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

10.  Comparing disease activity indices in ulcerative colitis.

Authors:  A J Walsh; A Ghosh; A O Brain; O Buchel; D Burger; S Thomas; L White; G S Collins; S Keshav; S P L Travis
Journal:  J Crohns Colitis       Date:  2013-10-10       Impact factor: 9.071

View more
  6 in total

Review 1.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

2.  Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.

Authors:  Sun-Ho Lee; Min-Ju Kim; Kiju Chang; Eun Mi Song; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Kyung-Jo Kim; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Byong Duk Ye
Journal:  BMC Gastroenterol       Date:  2017-10-23       Impact factor: 3.067

3.  Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.

Authors:  Fangwen Zou; Xuemei Wang; Isabella C Glitza Oliva; Jennifer L McQuade; Jennifer Wang; Hao Chi Zhang; John A Thompson; Anusha S Thomas; Yinghong Wang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

4.  Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission.

Authors:  Corina Silvia Pop; Petruta Violeta Filip; Sorina Laura Diaconu; Clara Matei; Florentina Furtunescu
Journal:  Medicina (Kaunas)       Date:  2020-12-31       Impact factor: 2.430

5.  Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.

Authors:  Jun Urushikubo; Shunichi Yanai; Shotaro Nakamura; Keisuke Kawasaki; Risaburo Akasaka; Kunihiko Sato; Yosuke Toya; Kensuke Asakura; Takahiro Gonai; Tamotsu Sugai; Takayuki Matsumoto
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

6.  Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study.

Authors:  Shiro Nakamura; Hirotsugu Imaeda; Hiroki Nishikawa; Masaki Iimuro; Minoru Matsuura; Hideo Oka; Junsuke Oku; Takako Miyazaki; Hirohito Honda; Kenji Watanabe; Hiroshi Nakase; Akira Andoh
Journal:  Intest Res       Date:  2018-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.